InsiderDB

Lobbying disclosures · Lobbying report

SRPT: third_quarter 2026 lobbying report

H.R. 9260 - LHHS Appropriations Rare Pediatric Disease Priority Review Voucher (PRV) Program Issues related to patient access to treatment National Security Commission on emerging biotechnology policy proposals Issues related to Section 232

Follow SRPT
Became public
Oct 19, 2026, 4:58 PM EDT
Event / period date
Not stated
Collected
Nov 11, 2026, 10:11 AM EST

Why this is connected

Exact legal-name match: Sarepta Therapeutics, Inc. (https://www.sec.gov/Archives/edgar/data/873303/).

Reported lobbying amounts

Expenses: $160,000.00

These are different reporting measures. They are not added together or treated as spending on one particular bill.

Source evidence

Read the source excerpt or record
{"url":"https://lda.gov/api/v1/filings/dafeff09-242c-422b-bd8c-9a9bd0ab96be/","filing_uuid":"dafeff09-242c-422b-bd8c-9a9bd0ab96be","filing_type":"Q3","filing_type_display":"3rd Quarter - Report","filing_year":2026,"filing_period":"third_quarter","filing_period_display":"3rd Quarter (July 1 - Sep 30)","filing_document_url":"https://lda.gov/filings/public/filing/dafeff09-242c-422b-bd8c-9a9bd0ab96be/print/","filing_document_content_type":"text/html","income":null,"expenses":"160000.00","expenses_method":"A","expenses_method_display":"A","posted_by_name":"Jennie Unger Skelton","dt_posted":"2026-10-19T16:58:11-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":"United States of America","registrant_address_1":"c/o 28 Liberty Ship Way, Suite 2815","registrant_address_2":null,"registrant_different_address":false,"registrant_city":"Sausalito","registrant_state":"CA","registrant_zip":"94965","registrant":{"id":401103510,"url":"https://lda.gov/api/v1/registrants/401103510/","house_registrant_id":null,"name":"SAREPTA THERAPEUTICS, INC.","description":"Biopharmaceutical company","address_1":"c/o 28 Liberty Ship Way, Suite 2815","address_2":null,"address_3":null,"address_4":null,"city":"Sausalito","state":"CA","state_display":"California","zip":"94965","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"JENNIE UNGER SKELTON","contact_telephone":"+1 415-903-2800","dt_updated":"2026-07-23T16:08:48.090815-04:00"},"client":{"id":199232,"url":"https://lda.gov/api/v1/clients/199232/","client_id":12,"name":"SAREPTA THERAPEUTICS, INC.","general_description":null,"client_government_entity":false,"client_self_select":true,"state":"CA","state_display":"California","country":"US","country_display":"United States of America","ppb_state":"CA","ppb_state_display":"California","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2014-12-01"},"lobbying_activities":[{"general_issue_code":"BUD","general_issue_code_display":"Budget/Appropriations","description":"H.R. 9260 - LHHS Appropriations","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":153690,"prefix":null,"prefix_display":null,"first_name":"MADISON","nickname":null,"middle_name":null,"last_name":"SMITH","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Rare Pediatric Disease Priority Review Voucher (PRV) Program Issues related to patient access to treatment","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":153690,"prefix":null,"prefix_display":null,"first_name":"MADISON","nickname":null,"middle_name":null,"last_name":"SMITH","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"SCI","general_issue_code_display":"Science/Technology","description":"National Security Commission on emerging biotechnology policy proposals","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":153690,"prefix":null,"prefix_display":null,"first_name":"MADISON","nickname":null,"middle_name":null,"last_name":"SMITH","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TRD","general_issue_code_display":"Trade (domestic/foreign)","description":"Issues related to Section 232","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":153690,"prefix":null,"prefix_display":null,"first_name":"MADISON","nickname":null,"middle_name":null,"last_name":"SMITH","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}

Congressional trading in SRPT

These disclosures provide context. Their presence does not establish a link between a trader and the event.

Original documents control. Public records can be amended, and company connections may require interpretation. Nothing here is investment advice.